Literature DB >> 25279185

Predominance of ERG-negative high-grade prostate cancers in African American men.

James Farrell1, Denise Young2, Yongmei Chen2, Jennifer Cullen2, Inger L Rosner1, Jacob Kagan3, Sudhir Srivastava3, David G McLEOD1, Isabell A Sesterhenn4, Shiv Srivastava2, Gyorgy Petrovics2.   

Abstract

Erythroblast transformation-specific-related gene (ERG) fusions, the most common and validated prostate cancer (CaP) genome alteration, result in alterations in the expression of the ERG oncoprotein. Significantly lower frequencies of ERG have been reported in tumors of African American (AA) in comparison to Caucasian American (CA) men. Building on our preliminary observations, this study has focused on the increased association of the ERG-negative status with higher-grade prostate tumors in AA men. Representative whole-mount prostate sections from a matched cohort of 63 AA and 63 CA men with Gleason scores of 4+3 and those with Gleason scores of 8-10 were analyzed for ERG oncoprotein by immunohistochemistry. The striking finding of this study was that ERG expression was 3 times more likely to be present in the higher-grade index tumors of CA men compared to AA men (31 of 63 vs. 10 of 63 patients, respectively; P<0.0001). Although the mechanisms underlying these differences have not been elucidated, the present study along with our previous observations underscores that ERG typing may enhance the understanding of ethnic differences and future targeted therapy of CaP.

Entities:  

Keywords:  erythroblast transformation-specific-related gene; ethnicity; prostate cancer; race; transmembrane protease serine 2 gene fusion

Year:  2014        PMID: 25279185      PMCID: PMC4179793          DOI: 10.3892/mco.2014.378

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  19 in total

1.  TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Authors:  Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou
Journal:  Prostate       Date:  2010-09-28       Impact factor: 4.104

Review 2.  Common gene rearrangements in prostate cancer.

Authors:  Mark A Rubin; Christopher A Maher; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

3.  Antibody-based detection of ERG rearrangement-positive prostate cancer.

Authors:  Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

Review 4.  Clinical potential of the ERG oncoprotein in prostate cancer.

Authors:  Philip Rosen; Isabell A Sesterhenn; Stephen A Brassell; David G McLeod; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2012-02-14       Impact factor: 14.432

5.  Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.

Authors:  Kendra Schwartz; Isaac J Powell; Willie Underwood; Julie George; Cecilia Yee; Mousumi Banerjee
Journal:  Urology       Date:  2009-12       Impact factor: 2.649

Review 6.  Biological determinants of health disparities in prostate cancer.

Authors:  Damali N Martin; Adrienne M Starks; Stefan Ambs
Journal:  Curr Opin Oncol       Date:  2013-05       Impact factor: 3.645

7.  Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

Authors:  Philip Rosen; David Pfister; Denise Young; Gyorgy Petrovics; Yongmei Chen; Jennifer Cullen; Diana Böhm; Sven Perner; Albert Dobi; David G McLeod; Isabell A Sesterhenn; Shiv Srivastava
Journal:  Urology       Date:  2012-08-28       Impact factor: 2.649

8.  Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Authors:  Kevin R Rice; Yongmei Chen; Amina Ali; Eric J Whitman; Amy Blase; Mona Ibrahim; Sally Elsamanoudi; Stephen Brassell; Bungo Furusato; Norbert Stingle; Isabell A Sesterhenn; Gyorgy Petrovics; Siobhan Miick; Harry Rittenhouse; Jack Groskopf; David G McLeod; Shiv Srivastava
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

9.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Authors:  B Furusato; S-H Tan; D Young; A Dobi; C Sun; A A Mohamed; R Thangapazham; Y Chen; G McMaster; T Sreenath; G Petrovics; D G McLeod; S Srivastava; I A Sesterhenn
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-29       Impact factor: 5.554

Review 10.  Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.

Authors:  James Farrell; Gyorgy Petrovics; David G McLeod; Shiv Srivastava
Journal:  Int J Mol Sci       Date:  2013-07-25       Impact factor: 5.923

View more
  20 in total

Review 1.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

2.  RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Authors:  Yongquan Wang; Jianghua Wang; Li Zhang; Omer Faruk Karatas; Longjiang Shao; Yiqun Zhang; Patricia Castro; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

3.  Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Authors:  Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Eur Urol Focus       Date:  2017-03-11

Review 4.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

Review 5.  Race and prostate cancer: genomic landscape.

Authors:  Camilo Arenas-Gallo; Jude Owiredu; Ilon Weinstein; Patrick Lewicki; Spyridon P Basourakos; Randy Vince; Bashir Al Hussein Al Awamlh; Fredrick R Schumacher; Daniel E Spratt; Christopher E Barbieri; Jonathan E Shoag
Journal:  Nat Rev Urol       Date:  2022-08-09       Impact factor: 16.430

6.  MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.

Authors:  Li Zhang; Jianghua Wang; Yongquan Wang; Yiqun Zhang; Patricia Castro; Longjiang Shao; Arun Sreekumar; Nagireddy Putluri; Nilanjan Guha; Saligrama Deepak; Arunkumar Padmanaban; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

7.  CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer.

Authors:  Scott A Tomlins; Edward M Schaeffer; Tamara L Lotan; Farzana A Faisal; Sanjana Murali; Harsimar Kaur; Thiago Vidotto; Liana B Guedes; Daniela Correia Salles; Vishal Kothari; Jeffrey J Tosoian; Sumin Han; Daniel H Hovelson; Kevin Hu; Daniel E Spratt; Alexander S Baras
Journal:  Clin Cancer Res       Date:  2020-01-22       Impact factor: 12.531

Review 8.  Prostate cancer: Race and prostate cancer personalized medicine: the future.

Authors:  Stephen Freedland
Journal:  Nat Rev Urol       Date:  2018-01-16       Impact factor: 14.432

9.  Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.

Authors:  Dana Hashim; Amparo G Gonzalez-Feliciano; Thomas U Ahearn; Andreas Pettersson; Lauren Barber; Claire H Pernar; Ericka M Ebot; Masis Isikbay; Stephen P Finn; Edward L Giovannucci; Rosina T Lis; Massimo Loda; Giovanni Parmigiani; Tamara Lotan; Philip W Kantoff; Lorelei A Mucci; Rebecca E Graff
Journal:  Int J Cancer       Date:  2019-07-27       Impact factor: 7.396

Review 10.  miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.

Authors:  Clayton Yates; Mark D Long; Moray J Campbell; Lara Sucheston-Campbell
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.